Continuing Education Online Courses


Browse online courses available for Continuing Education Credit.

Click here to view more online courses and resources for clinicians.

2022 CE Courses
2021 CE Courses
2020 CE Courses
Collapse Mechanisms of Immune-Related Adverse Events

Please note: this course is no longer eligible for continuing education credits.

 

Published December 24, 2020

 

Course Description

This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


Faculty
Pradnya Patil, MD, FACP

Hematology/Oncology Fellow

Taussig Cancer Institute, Cleveland Clinic


 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Discuss the mechanisms of peripheral and central immune tolerance.
  • Describe the biological pathways involved in mediating autoimmune reactions.
  • Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

 


Continuing Education Information

 

Credit Available: December 24, 2020 - December 24, 2021

 

Estimated time to complete activity: 0.5 hour

 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

  PIM_logo.pngsitc_log_color.png

 

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2520-H01-P)

Type of Activity: Knowledge


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Pradnya Patil, MD, FACP: Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

 

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: December 24, 2020

Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.50 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Mechanisms of Immune-Related Adverse Events
    Collapse Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade

    Published December 1, 2020

    Check out the updated version with new FDA drug approvals (As of 03/20/2023*), Available now......

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.


    Click on image for FREE PREVIEW


     

     

     

     

     

     

     

     

     

     

    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Robert L. Ferris, MD, PhD
    Hillman Professor of Oncology
    Director, UPMC Hillman Cancer Center
    Associate Vice Chancellor for Cancer Research
    University of Pittsburgh Medical Center, Pittsburgh, PA

     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Mechanisms of Checkpoint
    Blockade in Immunotherapy

    • Describe the basis for co-stimulation in T cell activation and priming.
    • Explain the mechanisms and consequences of co-inhibitory immune checkpoint receptors (ICR).
    • Identify negative downstream regulatory motifs and pathways associated with ICR signaling.
    • Distinguish the distinct activities of antibodies that target PD-1 compared to those that target PD-L1

    Biomarkers of Response to ICB and General Clinical Utility

    • Describe major biomarkers for patient eligibility for the use of immune checkpoint blockade across cancers (PD-L1 expression and extent, IFN signature, CD8 infiltration, Tumor Mutational Burden) and their relative value for prediction of clinical benefit.
    • Distinguish between validated and investigational biomarkers.
    • Describe the use of biomarkers to predict ORR, PFS and OS.
    • Identify patient-specific factors that may predict response (tumor burden, prior chemotherapy exposure, age, gender, site of disease, prior radiotherapy, etc.).
    Immune Checkpoint Inhibitors and Combination Approaches
    • Describe general clinical benefits of ICB with PD-1 or CTLA-4 monotherapy, or ICB combinations (including IO+IO and IO+other cancer therapy combinations).
    • Distinguish the benefits, dose and schedules of combination ICB versus the benefits, dose and schedule of conventional therapies (chemotherapy, radiation therapy and targeted therapies).
    • Identify validated vs investigational ICB combinations, and relevant cancer types.
    Monitoring Response to Checkpoint Blockade
    • Distinguish response criteria in ICB vs standard cancer treatment.
    • Describe kinetics and patterns of response to ICB.
    • Distinguish pseudoprogression from true disease progression.
    • Identify when to suspend or discontinue ICB treatment.


     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  December 1, 2022
    Date of CE Expiration: December 1, 2023
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Physicians / Nurses / Pharmacist

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™ for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
     

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Robert

    Ferris

    Aduro Biotech, Inc; Amgen; Astra-Zeneca/MedImmune; Bain Capital Life Sciences; BMS; EMD Serono; GSK; Iovance Biotherapeutics, Inc; Lilly; MacroGenics, Inc; Merck; Nanobiotix; Numab Therapeutics AG; Oncorus, Inc; Ono Pharmaceutical Co. Ltd; Pfizer; PPD (Benitec, Immunicum); Regeneron Pharmaceuticals, Inc; Tesaro; Torque Therapeutics; TTMS; VentiRx Pharmaceuticals:Consulting Fees

    Astra-Zeneca/MedImmune; BMS; Merck; Tesaro; TTMS:Contracted Research

     

    Janssen, Eli Lilly, Scibase, DermTech, BMS, Pfizer:Partner Consulting Fees

     

    Regeneron, Janssen, BMS, Abbvie, Novartis, BI, Castle Biosciences, Eli Lilly: Partner Contracted Research

     

    Jose

    Lutzky

    Castle, Kimera Labs, Array, Iovance: Consulting Fees
     

    BMS, Novartis, Iovance, Replimune, Regeneron: Contracted Research

     

    Method of Participation and Request for Credit
    During the period 12/1/22 through 12/1/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: December 01, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 1.50 hours Contact Hour
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 1.50 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade
    Collapse Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts

    Published October 26, 2020

    Check out our updated version- Certificate in Cancer Immunotherapy - Module 2 (As of 11/14/2022*), Available now....

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.


    Click on image for FREE PREVIEW


     

     

     

     

     

     

     




    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Hussein Tawbi, MD, PhD
    Deputy Chair and Professor, Department of Melanoma Medical Oncology
    Director of Melanoma Clinical Research & Early Drug Development
    Co-Director, MD Anderson Brain Metastasis Clinic
    University of Texas MD Anderson Cancer Center, Houston, TX
     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basis of Tumor Immunosurveillance and Immunotherapy

    • Describe how the immune system recognizes and eliminates cancer cells, including the concept of immunologic memory.
    • Characterize the function of specific immune cell populations in mediating tumor immunotherapy and/or immune suppression.
    • Distinguish between immunosurveillance, immunoediting and immunotherapy of cancer.
    • Identify the implications of immune depleted, excluded and infiltrated tumor microenvironments.
    • Identify how both central and peripheral tolerance can impact immunosurveillance and immunotherapy.
    • Describe the difference between primary and acquired resistance to immunotherapy.
    • Apply concepts of the cancer-immunity cycle to identify how biomarkers inform and influence tumor immunotherapy.

    Immunologic effects of other therapies

    • Describe the immunologic effects of standard cancer therapeutics on the tumor microenvironment and immune system.
    • Describe the potential impact of other, non-cancer agents, on tumor immunotherapy responses and toxicities.
    • Characterize the impact of standard cancer treatments on the efficacy of cancer immunotherapy.
    • Characterize the impact of standard cancer treatments on the toxicity of cancer immunotherapy.
    • Distinguish total body versus focal radiotherapy effects.
    • Recognize the impact of intratumoral injection and other local therapies on the tumor microenvironment and anti-tumor immune response.


     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  10/27/22
    Date of CE Expiration: 10/27/23
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Physicians / Nurses / Pharmacist

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™ for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
     

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Hussein

    Tawbi

    Genentech, BMS, Novartis, Merck, Array: Consulting Fees

    Genentech, BMS, Novartis, Merck, GSK: Contracted Research
     

    Silvia

    Formenti

    Grant/Research support from: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron,Eisai, Merck: Contracted Research

    Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Accuray: Honoria

    Method of Participation and Request for Credit
    During the period 10/27/2022 through 10/27/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: October 26, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 1.50 hours Contact Hour
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 1.50 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts
    Collapse Immunotherapy for the Treatment of Breast & Gynecologic Cancers

    This version of the course is no longer available for credit. To access the accredited version go here to find the Immunotherapy for the Treatment of Breast and Gynecologic Cancers that is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Published August 11, 2020

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the still emerging applications of Breast and Gynecologic Cancer Immunotherapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for Breast and Gynecologic Cancer.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Evanthia Roussos Torres, MD, PhD
    Assistant Professor of Medicine, Oncology
    University of Southern California
    Norris Comprehensive Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
    • Implement cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 8/11/20 - 8/11/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2249-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Evanthia Roussos Torres, MD, PhD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 8/11/20 through 8/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Breast & Gynecologic Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

    Original Course Date: August 11, 2020

    Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Breast & Gynecologic Cancers
    Collapse Immunotherapy for the Treatment of Microsatellite Instability-High Cancers

    Please note, this course is no longer eligible to receive CE credits.

    Published July 29,2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers, provides background on MSI and an overview of immunotherapy treatment for MSI-high populations. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for MSI-high cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    John C. Leighton, Jr., MD
    Division Chair, Hematology and Medical Oncology
    Einstein Healthcare Network

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe microsatellite instability and the implications for immunotherapy treatment
    • Provide cancer immunotherapy treatment for microsatellite instability – high cancers
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 7/29/20 - 7/29/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2214-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    John C. Leighton, Jr., MD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/29/20 through 7/29/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: July 29, 2020

    Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Microsatellite Instability-High Cancers
    Collapse Optimizing Management of Adverse Events Associated with Immunotherapy

    While it is well established that immunotherapies have unique toxicity profiles, effective management is not clearly defined and a challenge for many cancer teams. As evidence emerges on severity and onset of immune-related adverse events (irAEs), it is imperative that clinicians stay abreast of strategies to improve awareness, risk-assessment, monitoring, and management of irAEs including dosing modifications for immunotherapies. Experts will discuss these critical issues as well as the importance of a coordinated approach with multiple specialists for effective irAE management.

     

    This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

     

     

    Learning Objectives:

    • Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
    • Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Optimizing Management of Adverse Events Associated with Immunotherapy
    Collapse Life After Immunotherapy: Coordinating Care and Survivorship Plans

    Effective survivorship care requires coordination among a team of specialists, as well as counseling and education that enables patients to effectively manage their post-treatment health and well-being. As the long-term effects of checkpoint inhibitors are incorporated into survivorship planning, a multidisciplinary panel will discuss evidence-based strategies to provide a framework to address the unique needs of patients treated with immunotherapy.

     

    This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

     

     

    Learning Objectives:

    • Apply recent guidelines and expert recommendations for the creation of comprehensive survivorship plans for patients who have received immune checkpoint inhibitors
    • Plan strategies on developing survivorship plans within your multidisciplinary cancer care team

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Life After Immunotherapy: Coordinating Care and Survivorship Plans
    Collapse Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

    Image previewImmunotherapy has permeated the cancer treatment landscape among several tumor types and treatment settings. With key late-stage clinical trials underway, immunotherapy experts provide critical updates on emerging data, recent approvals, and promising immunotherapy combinations with other classes of agents. Updates will be provided across solid tumors with opportunities to ask critical clinical questions and receive expert answers.

     

    This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

     

     

    Learning Objectives:

    • Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
    • Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
    • Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
    • Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations
    Collapse Immunotherapy for the Treatment of Lung Cancer

    This version of the course is no longer available for credit.  To access the accredited version, go here to find the Immunotherapy for the Treatment of Lung Cancer that is a CME-, CPE-, CNE-, and MOC-certified activity. 

     

    Published July 15, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through an in-depth case study. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Deepa Rangachari, M.D.
    Assistant Professor of Medicine, Harvard Medical School
    Thoracic Oncology Program, Beth Israel Deaconess Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available:  July 15, 2020 - July 15, 2021

    Approximate Time to Complete: 60 minutes

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2190-H01)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Deepa Rangachari, MD: Contracted research support from Bristol Myers Squibb, Novocure, and Abbvie/Stemcentrx; consulting fees from Astra Zeneca, DynaMed, and Advance Medical/Teladoc Health


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/15/20 through 7/15/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Lung Cancer.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

    Original Course Date: July 15, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACPE: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Lung Cancer
    Collapse Refining Patient Selection for Biomarker-Directed Immunotherapy

    Access Course

     

    As diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.

     

    This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

     

    Learning Objectives:

    • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
    • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: June 10, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Refining Patient Selection for Biomarker-Directed Immunotherapy